Adverse Events and Complications with Intragastric Balloons: a Narrative Review (with Video)

Ribeiro, Igor Braga; Kotinda, Ana Paula Samy Tanaka; Sánchez-Luna, Sergio A.; Mancini, Fabio Catache; Souza, Thiago Ferreira de; Matuguma, Sérgio; Sakai, Christiano; Rocha, Robson S.; Luz, Gustavo de Oliveira; Santos, Marcos Eduardo Lera dos; Chaves, Dalton Marques; Franzini, Tomazo; Moura, Eduardo Turiani Hourneaux de

doi:10.1007/s11695-021-05352-7

Cited by 12 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, no serious complications were identified, underscoring the fact that the use of an IGB is safe [29][30][31][32][33][34]. The mean weight loss, quantified immediately after IGB removal, was 16.8 kg, similar to that reported in other studies in which an IGB was left in place for six months [35,36].…”

Section: Discussionsupporting

confidence: 86%

Gastric Emptying and Its Correlation With Weight Loss and Body Mass Index in Patients With an Intragastric Balloon: A Prospective Study With Six Years of Follow-Up

Barrichello¹,

Ribeiro²,

Souza³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundObesity is the most well-established and prolonged pandemic in modern society. Having a better understanding of the available tools is important to improve weight loss and make the strategies more productive. This study aims to evaluate the effect of intragastric balloon (IGB) on gastric emptying time, its relationship with weight loss after IGB removal, and weight maintenance after six years. MethodologyThis prospective study analyzed data from patients undergoing IGB placement. A six-years follow-up was performed and data about weight maintenance were collected. We analyzed the impact of the IGB on gastrointestinal motility and its correlation with weight loss. ResultsOf the 20 patients included in the study, 52.4% were diagnosed with class I obesity and 47.6% with class II obesity. The mean weight of the patients was 96.5 ± 11.9 kg at baseline, 79.6 ± 11.4 kg at the time of IGB removal, 81.8 ± 9.1 kg at six months, and 93.2 ± 14.3 kg six years after IGB removal. The mean difference between the initial weight and that measured immediately after IGB removal was 16.68 ± 5.71 kg. Regarding gastric emptying time, there was a difference in retention on comparing the measurement before balloon placement to that after the balloon was in place (72.9% vs. 86.8%) after one hour of food intake. Comparing two hours after food intake, patients before IGB placement had a 30.6% food retention, while patients with IGB in place had a 69.2% retention. ConclusionsIn patients with class I or II obesity, the use of an IGB delayed gastric emptying of foods but showed no direct correlation with weight loss. Weight loss achieved after IGB placement was maintained in half of the patients at a six-year follow-up.

show abstract

Section: Discussionsupporting

confidence: 86%

Gastric Emptying and Its Correlation With Weight Loss and Body Mass Index in Patients With an Intragastric Balloon: A Prospective Study With Six Years of Follow-Up

Barrichello¹,

Ribeiro²,

Souza³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…The safety profile showed a tendency similar to that of previous reports. 14,18 Pharmacotherapy is less effective than IGB treatment. In terms of %TBWL, pharmacotherapy showed 5% to 8% weight loss compared to 7% to 14% with IGB treatment.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of intragastric balloon for obesity in Korea

Lee¹,

Nam

Choi

et al. 2023

Clin Endosc

View full text Add to dashboard Cite

Background/Aims: Intragastric balloon (IGB) is the only available endoscopic bariatric and metabolic therapy in Korea. End-ball (Endalis) has the longest history of clinical use among the IGBs available in Korea. However, little clinical data on this system have been reported. In this study, we aimed to evaluate the efficacy and safety of End-ball in Korea. Methods: We performed a retrospective cohort study of patients who underwent IGB insertion (End-ball) from 2013 to 2019. Demographic and anthropometric data were collected. The efficacy and safety of IGB treatment were analyzed. Results: In total, 80 patients were included. Mean age was 33.7 years and 83.8% were female. Initial body mass index was 34.48±4.69 kg/m 2 . Body mass index reduction was 3.72±2.63 (kg/m 2 ) at the time of IGB removal. Percent of total body weight loss (%TBWL) was 10.76%±6.76%. Percentage excess body weight loss was 43.67%±27.59%. Most adverse events were minor, and 71.4% of participants showed nausea, vomiting, or abdominal pain. Conclusions: IGB treatment showed good efficacy and safety profile in Korean patients with obesity. In terms of %TBWL and percentage excess body weight loss, the efficacy was similar to that in the Western population.

show abstract

“…However, the persistence of obstructive symptoms may require early IGB removal, which usually occurs in less than 5% of patients limiting their efficacy [ 23 ]. Serious AEs (SAE) include mucosal injury or perforation of the stomach or esophagus, gastrointestinal obstruction due to the migration of the balloon, gastric outflow obstruction, and infections due to bacterial overgrowth in the fluid filling the balloon [ 23 , 24 ]. A meta-analysis by Trang et al conducted on a total of 938 patients who underwent the positioning of different types of IGBs, showed that nausea and vomiting were very frequent after an IGB positioning (63.3%; 95%CI 61.5–65.2% and 55.3%; 95%CI 53.6–57% respectively) whereas the account rate of SAEs was lower (5.2%; 95% CI 4.8–5.6%) [ 25 ].…”

Section: Primary Bariatric Endoscopic Therapiesmentioning

confidence: 99%

A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going

et al. 2023

View full text Add to dashboard Cite

Background: Obesity is a chronic disease that impairs quality of life and leads to several comorbidities. When conservative therapies fail, bariatric surgical options such as Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the most effective therapies to induce persistent weight loss. Over the last two decades, bariatric endoscopy has become a valid alternative to surgery in specific settings. Primary bariatric endoscopic therapies: Restrictive gastric procedures, such as intragastric balloons (IGBs) and endoscopic gastroplasty, have been shown to be effective in inducing weight loss compared to diet modifications alone. Endoscopic gastroplasty is usually superior to IGBs in maintaining weight loss in the long-term period, whereas IGBs have an established role as a bridge-to-surgery approach in severely obese patients. IGBs in a minority of patients could be poorly tolerated and require early removal. More recently, novel endoscopic systems have been developed with the combined purpose of inducing weight loss and improving metabolic conditions. Duodenal mucosal resurfacing demonstrated efficacy in this field in its early trials: significant reduction from baseline of HbA1c values and a modest reduction of body weight were observed. Other endoscopic malabsorptive have been developed but need more evidence. For example, a pivotal trial on duodenojejunal bypasses was stopped due to the high rate of severe adverse events (hepatic abscesses). Optimization of these more recent malabsorptive endoscopic procedures could expand the plethora of bariatric patients that could be treated with the intention of improving their metabolic conditions. Revisional bariatric therapies: Weight regain may occur in up to one third of patients after bariatric surgery. Different endoscopic procedures are currently performed after both RYGB and SG in order to modulate post-surgical anatomy. The application of argon plasma coagulation associated with endoscopic full-thickness suturing systems (APC-TORe) and Re-EndoSleeve have shown to be the most effective endoscopic treatments after RYGB and SG, respectively. Both procedures are usually well tolerated and have a very low risk of stricture. However, APC-TORe may sometimes require more than one session to obtain adequate final results. The aim of this review is to explore all the currently available primary and revisional endoscopic bariatric therapies focusing on their efficacy and safety and their potential application in clinical practice.

show abstract

Adverse Events and Complications with Intragastric Balloons: a Narrative Review (with Video)

Cited by 12 publications

References 32 publications

Gastric Emptying and Its Correlation With Weight Loss and Body Mass Index in Patients With an Intragastric Balloon: A Prospective Study With Six Years of Follow-Up

Gastric Emptying and Its Correlation With Weight Loss and Body Mass Index in Patients With an Intragastric Balloon: A Prospective Study With Six Years of Follow-Up

Efficacy and safety of intragastric balloon for obesity in Korea

A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going

Contact Info

Product

Resources

About